# FDA 483 - Robert M. Haws, M.D. - September 04, 2020

Source: https://www.globalkeysolutions.net/records/483/robert-m-haws-md/906bb9d6-60f7-4348-9277-bdaa950d6681

> FDA 483 for Robert M. Haws, M.D. on September 04, 2020. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Robert M. Haws, M.D.
- Inspection Date: 2020-09-04
- Product Type: drugs
- Office Name: Minneapolis District Office
- Summary: An FDA inspection of Robert M. Haws, M.D. in Marshfield, WI, identified a significant deviation from an investigational plan. The clinical investigator failed to adhere to the study protocol for dose escalation in a clinical trial, leading to potential subject safety concerns. This non-compliance involved multiple subjects and specific protocol sections related to study design and drug dose adjustments.

## Related Officers

- [Bioresearch Monitoring Specialis](https://www.globalkeysolutions.net/people/denise-l-burosh/075a442f-67e0-4a65-9c09-e8819a329773)

Company: https://www.globalkeysolutions.net/companies/robert-m-haws-md/e6ec4931-68c7-4106-aef7-4dcd0cb5b99b

Office: https://www.globalkeysolutions.net/offices/minneapolis-district-office/c79fc8dc-f884-48fc-ba80-2947f662511d